Caleb Masterson, DO
Otolaryngology · Florence, ALNPI 1487073649
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,964 of the $6,519 with a category attached, or 76.2%. Stryker accounts for 80.6% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2021 at $1,822 and has fallen 59.3% since, to $742 in 2025.
Across 177 payments — averaging $36.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$5K
- Optinose US, Inc.$327
- Sanofi$194
- Aerin Medical Inc.$177
- Intersect ENT, Inc.$155
- ARS Pharmaceuticals Operations, Inc.$93
- plus $316 from 7 others
What the payments were for
- Travel & lodging$1,54024%
- Food & beverage$4,96476%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 121 | $5,256 |
| Optinose US, Inc. | 16 | $327 |
| Sanofi | 9 | $194 |
| Aerin Medical Inc. | 5 | $177 |
| Intersect ENT, Inc. | 6 | $155 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $93 |
| Regeneron Healthcare Solutions, Inc. | 5 | $92 |
| GSK | 4 | $72 |
| Neurent Medical Limited | 2 | $45 |
| Acclarent, Inc | 1 | $37 |
| Medtronic | 2 | $37 |
| KARL Storz Endoscopy-america | 1 | $26 |
| Xoran Technologies LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,519 in reported general payments places this provider in the 85th percentile of 155 otolaryngology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CeftriaxoneCeftriaxone Sodium | 24 | $15,431 |
| Azelastine Hcl | 131 | $3,797 |
| Epinephrine | 19 | $3,683 |
| Cephalexin | 209 | $1,368 |
| Ipratropium Bromide | 34 | $939 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 162 | $494 |
| Omeprazole | 24 | $366 |
| Ondansetron OdtOndansetron | 59 | $176 |
| Fluticasone Propionate | 11 | $118 |
| Ondansetron Hcl | 41 | $42 |
| Promethazine Hcl | 31 | $26 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Florence
- John DavisHoover$251K
- William McFeelyHuntsville$70K
- Michael SillersBirmingham$53K
- Justin TurnerBirmingham$34K
- Bradford WoodworthBirmingham$27K
- Patrick OwensBirmingham$26K
- Kirk WithrowBirmingham$22K
- Do-Yeon ChoBirmingham$19K
- William BlytheOpelika$19K
- Andrew FusonBirmingham$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.